Eight autopsy cases of melanoma brain metastases showing angiotropism and pericytic mimicry. Implications for extravascular migratory metastasis

2019 ◽  
Vol 46 (8) ◽  
pp. 570-578 ◽  
Author(s):  
Ann‐Katrin Rodewald ◽  
Elisabeth J. Rushing ◽  
Daniel Kirschenbaum ◽  
Joanna Mangana ◽  
Christiane Mittmann ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Melanoma Brain Metastases ◽  
Pericytic Mimicry

Development of a New Model of Melanoma Brain Metastases

2012 ◽  
Vol 73 (S 02) ◽  
Author(s):  
M. Amit ◽  
L. Laider-Trejo ◽  
A. Shabtay ◽  
Z. Gil
Keyword(s):  
Brain Metastases ◽  
New Model ◽  
Melanoma Brain Metastases

scholarly journals Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1489
Author(s):  
John M. Rieth ◽  
Umang Swami ◽  
Sarah L. Mott ◽  
Mario Zanaty ◽  
Michael D. Henry ◽  
...  
Keyword(s):  
Overall Survival ◽  
Brain Metastases ◽  
Checkpoint Inhibitor ◽  
Checkpoint Inhibitors ◽  
Performance Status ◽  
Multivariable Analysis ◽  
Treatment Strategies ◽  
Poor Performance Status ◽  
Poor Overall Survival ◽  
Melanoma Brain Metastases

Brain metastases commonly develop in melanoma and are associated with poor overall survival of about five to nine months. Fortunately, new therapies, including immune checkpoint inhibitors and BRAF/MEK inhibitors, have been developed. The aim of this study was to identify outcomes of different treatment strategies in patients with melanoma brain metastases in the era of checkpoint inhibitors. Patients with brain metastases secondary to melanoma were identified at a single institution. Univariate and multivariable analyses were performed to identify baseline and treatment factors, which correlated with progression-free and overall survival. A total of 209 patients with melanoma brain metastases were identified. The median overall survival of the cohort was 5.3 months. On multivariable analysis, the presence of non-cranial metastatic disease, poor performance status (ECOG 2–4), whole-brain radiation therapy, and older age at diagnosis of brain metastasis were associated with poorer overall survival. Craniotomy (HR 0.66, 95% CI 0.45–0.97) and treatment with a CTLA-4 checkpoint inhibitor (HR 0.55, 95% CI 0.32–0.94) were the only interventions associated with improved overall survival. Further studies with novel agents are needed to extend lifespan in patients with brain metastases in melanoma.

scholarly journals Proteogenomic analysis of melanoma brain metastases from distinct anatomical sites identifies pathways of metastatic progression

2020 ◽  
Vol 8 (1) ◽  
Author(s):  
Erin M. Taylor ◽  
Stephanie D. Byrum ◽  
Jacob L. Edmondson ◽  
Christopher P. Wardell ◽  
Brittany G. Griffin ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Metastatic Progression ◽  
Melanoma Brain Metastases

scholarly journals Malignant melanoma brain metastases: Treatment results and prognostic factors - a single-center retrospective study

2015 ◽  
Vol 46 (6) ◽  
pp. 2439-2448 ◽  
Author(s):  
CHRISTIAN OSTHEIMER ◽  
CAROLINE BORMANN ◽  
ECKHARD FIEDLER ◽  
WOLFGANG MARSCH ◽  
DIRK VORDERMARK
Keyword(s):  
Prognostic Factors ◽  
Retrospective Study ◽  
Malignant Melanoma ◽  
Brain Metastases ◽  
Single Center ◽  
Treatment Results ◽  
Melanoma Brain Metastases

Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation – Authors' reply

2018 ◽  
Vol 19 (8) ◽  
pp. e367 ◽  
Author(s):  
Georgina V Long ◽  
Victoria Atkinson ◽  
Angela Hong ◽  
Grant A McArthur ◽  
Alexander M Menzies
Keyword(s):  
Brain Metastases ◽  
Melanoma Brain Metastases

PO-1226: Safety and outcomes of concurrent immunotherapy and radiation therapy for melanoma brain metastases

2020 ◽  
Vol 152 ◽  
pp. S645-S646
Author(s):  
A. Desagneaux ◽  
M.T. Leccia ◽  
I. Gabelle Flandin ◽  
A.-.M. Dols ◽  
A. Kastler ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Brain Metastases ◽  
Melanoma Brain Metastases
Sign in / Sign up

Export Citation Format

Share Document